RxDoctor Payments Data

Gifty Appiah

Family · Brooklyn, NYNPI 1730345745

Payments from drug & device makers

$1,160in general payments, 2019–2025

Across 47 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$323
  • Neurocrine Biosciences, Inc.$264
  • Urovant Sciences Inc$131
  • Idorsia Pharmaceuticals US Inc$109
  • Lilly USA, LLC$54
  • Otsuka America Pharmaceutical, Inc.$47
  • plus $231 from 7 others

What the payments were for

  • Food & beverage$1,05491%
  • Education$1069%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,160 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$93,340
Medicare patients
340
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine82$171,950
BiktarvyBictegrav/Emtricit/Tenofov Ala39$164,297
TivicayDolutegravir Sodium75$92,527
DescovyEmtricitabine/Tenofov Alafenam20$46,797
EliquisApixaban98$37,398
PrezcobixDarunavir/Cobicistat22$26,919
JardianceEmpagliflozin26$25,761
JanuviaSitagliptin Phosphate56$24,789
VraylarCariprazine Hcl29$20,866
EdurantRilpivirine Hcl22$16,176
OzempicSemaglutide12$12,221
IsentressRaltegravir Potassium15$12,174
AbrysvoRsv Vacc, Pref A And Pref B/Pf34$11,540
Divalproex Sodium256$7,298
Atovaquone14$6,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$323$171,95082 claims
PfizerEliquis, Abrysvo$16$48,938132 claims
Lilly USA, LLCOlanzapine$54$4,416271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →